advertisement
Humphries P 19
Showing records 1 to 19 | Display all abstracts from Humphries P108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
O'Callaghan J
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Chadderton N
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Delaney C
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Palfi A; Maloney DM
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
O'Connor M; van Batenburg-Sherwood J; van Batenburg-Sherwood J
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Carrigan M
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Schicht M
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Finnegan LK; Hanlon KS
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Lütjen-Drecoll E
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Shortall C
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Hudson N; Ni Dhubhghaill S
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
O'Reilly M; Humphries P
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Humphries P; Stanley C
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Cassidy L
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Keravala A
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Kenna PF; Millington-Ward S
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Chalberg T; Lawrence MS
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Farrar GJ
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Campbell M
Science advances 2023; 9: eadf6537